The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.

about

The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.

Item

http://www.wikidata.org/entity/Q52092512

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The TORC1/2 inhibitor TAK228 s ...... isplatin-induced cytotoxicity.

@en

The TORC1/2 inhibitor TAK228 s ...... isplatin-induced cytotoxicity.

@nl

type

Item

label

The TORC1/2 inhibitor TAK228 s ...... isplatin-induced cytotoxicity.

@en

The TORC1/2 inhibitor TAK228 s ...... isplatin-induced cytotoxicity.

@nl

prefLabel

The TORC1/2 inhibitor TAK228 s ...... isplatin-induced cytotoxicity.

@en

The TORC1/2 inhibitor TAK228 s ...... isplatin-induced cytotoxicity.

@nl

P1476

The TORC1/2 inhibitor TAK228 s ...... isplatin-induced cytotoxicity.

@en

P2093

Antoinette Price

http://www.w3.org/2001/XMLSchema#string

Brent A Orr

http://www.w3.org/2001/XMLSchema#string

Eric H Raabe

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Rubens

http://www.w3.org/2001/XMLSchema#string

Melanie F Weingart

http://www.w3.org/2001/XMLSchema#string

Sabrina Z Wang

http://www.w3.org/2001/XMLSchema#string

Sariah J Allen

http://www.w3.org/2001/XMLSchema#string

P2860

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

mTOR signaling in growth control and disease

A simple practice guide for dose conversion between animals and human

Defining the role of mTOR in cancer

Lin28: primal regulator of growth and metabolism in stem cells

Lin28 enhances tissue repair by reprogramming cellular metabolism

Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor

Dose translation from animal to human studies revisited

Integrative genomic approaches identify IKBKE as a breast cancer oncogene.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

P304

1361-1371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOX067

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Charles G Eberhart

P577

2017-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28582547

http://www.w3.org/2001/XMLSchema#string

P932

5604899

http://www.w3.org/2001/XMLSchema#string